Dyslipidemia among Patients with End Stage Renal Disease on Maintenance Hemodialysis

Abstract = 1005 times | PDF = 464 times

Main Article Content

Mohammed Ghazi Abdulhadi Mohammed Omer Mohammed Fenk Bakir Maarouf


Dyslipidemia has been suggested to be one of the factors that contribute to the high incidence of cardiovascular disease in hemodialysis patients. Previous studies suggest that end-stage renal disease may contribute to dyslipidemia. The aim of the study: to assess the prevalence of dyslipidemia in patients on maintenance hemodialysis. Patients and Methods: A case-control study was conducted from February 2015 until August 2015 in Ibn-Sena teaching hospital on 100 participants (52 males and 48 females), 50 were patients with end-stage renal disease on regular hemodialysis and 50 were age and gender-matched apparently healthy subjects as the control. Questioner used to collect data, a thorough examination was done including height and weight and BMI. A blood sample from all participants in fasting state was sent for the renal function test, complete blood picture, serum albumin, electrolytes, TG, total cholesterol, LDL and HDL measured by the enzymatic method, plasma atherogenic index calculated as [log (TG/HDL)].   Results: Age of the participants ranged between 18 - 70 years and the mean age was (44.45 ± 13.6) years. In HD group, the mean cholesterol  was  (3.29 + 0.73) mmol/l, serum TG (2.38 ± 0.56) mmol/l, LDL (1.91 ± 0.66) mmol/l, HDL (0.88 ± 0.2) mmol/l, atherogenic index (0.434 ± 0.16), while in control group, the mean cholesterol  was (4.17 ± 0.69) mmol/l, serum TG (1.6 ± 0.43) mmol/l, LDL (2.69 ± 0.63 ) mmol/l, HDL (1.066 ± 0.13) mmol/l, atherogenic index (0.177 ± 0.12).  The lipid abnormalities in hemodialysis group were high plasma atherogenic index in 84%, hypertriglyceridemia 50%, hypercholesterolemia 8% and high LDL  6% and low HDL in 48%, while in control group, high plasma atherogenic index in 34%, hypertriglyceridemia in 26%, hypercholesterolemia 14% high LDL 7% and low HDL in 16%. Conclusions: patients with end-stage renal disease on hemodialysis have significant dyslipidemia compared to control group characterized by hypertriglyceridemia, low HDL and high atherogenic index of plasma.


dyslipidemia, end-stage renal disease, hemodialysis, atherogenic index of plasma.


Download data is not yet available.

Article Details


[1] M.H. Dominiczak, M.J. Caslake, “Apolipoproteins: the metabolic role and clinical biochemistry applications,” Ann Clin Biochem, vol. 48, pp. 498-515, 2011.
[2] P.O. Attman, P. Alaupovic, “Lipid abnormalities in chronic renal insufficiency,” Kidney Int, vol. 39, pp. 516–523, 1991.
[3] P. Alaupovic, “Apolipoprotein composition as the basis for classifying plasma lipoproteins. Characterization of apoA- and apoB-containing lipoprotein families,” Prog Lipid Res, vol. 30, pp. 105–138, 1991.
[4] X. Wang, S.K. Peesapati, M.F. Renedo, S. Moktan, “Haemoglobin A1c levels in non-diabetic patients with end-stage renal disease (ESRD) receiving haemodialysis,” J Endocrinol Invest, vol. 27, pp. 7335, 2004.
[5] C. Douglas, “Malnutrition and Nutritional Assessment,” Harrison's principles of internal medicine, 18th Edition, McGraw Hill Company, vol. 75, pp. 609, 2012.
[6] R. Lokesh. M. Anwar, A. Sandhya, “A study of lipid profile in chronic renal failure patients undergoing hemodialysis,” IOSR Journal of Dental and Medical Sciences (IOSR-JDMS), vol. 15, pp. 01-03, 2016.
[7] S. Hariom, J. Tejas, H.G. Jignesh, P.B. Dipika, “Lipid profile and lipoprotein(a) in chronic renal failure patients with and without hemodialysis, Govt,” Medical College, Bhavnagar, Gujarat, India, M.P.Shah Medical College, Jamnagar, Gujarat, India, 2012.

[8] S.P. Sarah, “Impact of dyslipidemia in end-stage renal disease,” Department of Medicine, McGill University, Montreal, Canada, J Am Soc Nephrol, vol. 14, pp. 315–320, 2003.
[9] V. Luca, B. Salvatore, L. Antonio, C. Valeria, B. Annamaria, C. Giovanni, “Lipid disorders in patients with renal failure: Role in cardiovascular events and progression of chronic kidney disease,” vol. 14, pp. 12 – 15, 2016.
[10] U. Şükrü, Ö. Gülsüm, “Lipid Abnormalities in Hemodialysis Patients,” Karadeniz Technical University, School of Medicine, Department of Nephrology, Turkey, vol. 27, pp. 13, 2013.
[11] P. Grzegorz, A. Marcin, R. Eberhard, “Dyslipidemia in chronic kidney disease Pathogenesis and intervention,” Department of Nephrology, Endocrinology and Metabolic Diseases, Medical University of Silesia, Katowice, Poland, Department of Internal Medicine, Division of Nephrology, Ruperto Carola University, Nierenzentrum Heidelberg, Germany, vol. 34, pp. 23, 2009.
[12] N.C. Nzere, E.A.S. Bartimaeus, C.U. Okeke, “Lipid Profile in Chronic Renal Failure Patients on Dialysis,” Received, vol. 6, pp. 20, 2012.
[13] M.A. Somia, A. Mohammed, “The Effect of Haemodialysis on Plasma Cholesterol and triglycerides In Sudanese Patients with End- Stage Renal disease (ESRD),” Sudan University of Science & Technology, vol. 9, pp. 34, 2006.
[14] H.M Robert, M.D. Mark, “Effect of recombinant human erythropoietin on insulin, amino acid, and lipid metabolism in uremia,” pp. 97–104, 1996.
[15] G. Tetsuya, S. Hiroko, T. Toshio, M. Akefumi, M. Masatoshi, Y. Susumu, “Erythropoietin supplement increases plasma lipoprotein lipase and hepatic triglyceride lipase levels in hemodialysis patients,” Department of Internal Medicine, Kodama Hospital, and Third Department of Internal Medicine, Wakayama Medical College, Wakayama, Japan, pp. 213–215, 1999.
[16] M.S. Elisaf, N.P. Germanos, H.T. Bairaktari, M.B. Pappas, E.I. Koulouridis, K.C. Siamopoulos, “Effects of Conventional vs. Low-Molecular-Weight Heparin on Lipid Profile in Hemodialysis Patients,” Am J Nephrol, vol. 17, pp. 153–157, 1997.
[17] F. Wafa, M.H. Elham, A.A. Zean, “Evaluating the utility of plasma Atherogenic Index among several atherogenic parameters in patients with chronic renal Failure on maintenance hemodialysis,” Journal of the Faculty of Medicine, Baghdad University, 2012.
[18] S. Tetsuo, M. Ikuto, W. Yuzo, I. Kunitoshi, T. Yoshiharu, “Elevated non-high-density lipoprotein cholesterol (non-hdl-c) predicts atherosclerotic cardiovascular events in hemodialysis patients, Japanese Society for Dialysis Therapy,” 2011.
[19] O. Hiroaki, F.K. William, “Lipid abnormalities in end stage renal disease, Minneapolis,” Minnesota, USA, Nephrol Dial Transplant, vol. 13, pp. 45–49, 1998.
[20] N.F. Allon, Z.F. Stephen, “Reassessment of Albumin as a Nutritional Marker in Kidney Disease, Division of Nephrology,” Indiana University School of Medicine, Indianapolis, Indiana, Kidney Associates, Houston, Texas, 2010.
[21] A. Buthainah, A. Ajile, “Lipid Profile in Relation to Gender and Body Mass Index in Students of Al-Qadisiya Medical College,” Journal of Kufa for Chemical Science, vol. 2, pp. 105-115, 2012.
[22] L. Shamai, E. Lurix, M. Shen, G.M. Novaro, S. Szomstein, R. Rosenthal, “Association of body mass index and lipid profiles: evaluation of a broad spectrum of body mass index patients including the morbidly obese,” Cleveland Clinic Florida, Weston, USA, 2011.
[23] J. Aziz, N.A. Siddiqui, I.A. Siddiqui, A. Omair, “Relation of body mass index with lipid profile and blood pressure in young healthy students at Ziauddin Medical University,” Medical University, Karachi, 2003.
[24] R. Somesh, B. Singh, N. Verma, T. Sunita, N. Jagdish, C. Tulika, “Study of body mass index (BMI) and lipid profile of blood donors of north Indian population: across sectional study,” 2015.
[25] A. Tarig, A. AbdElkarim, F. Mohamed, “Effects of age and gender on serum lipid profile in over 55 years-old apparently healthy Sudanese individuals,” Asian Journal of Biomedical and Pharmaceutical Sciences, vol. 3, pp.10-14, 2013.